Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)Alfred L. Garfall, Amrita Krishnan, Niels W.C.J. van de Donk et al.|Blood|2020Cited by 60
Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated efficacy and safety results from MajesTEC-1.Ajay K. Nooka, Amrita Krishnan, Philippe Moreau et al.|Journal of Clinical Oncology|2022Cited by 13